As of 2025-03-21, the Relative Valuation of Inozyme Pharma Inc (INZY) is (19.57) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.00 USD, the upside of Inozyme Pharma Inc based on Relative Valuation is -2059.8%.
The range of the Relative Valuation is (18.90) - (24.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 16.7x | 14.3x |
| Forward P/E multiples | 5.1x - 15.6x | 10.4x |
| Fair Price | (18.90) - (24.78) | (19.57) |
| Upside | -1992.2% - -2580.5% | -2059.8% |
| Date | P/E |
| 2025-03-04 | -0.71 |
| 2025-03-03 | -0.69 |
| 2025-02-28 | -0.76 |
| 2025-02-27 | -0.76 |
| 2025-02-26 | -0.76 |
| 2025-02-25 | -0.75 |
| 2025-02-24 | -0.78 |
| 2025-02-21 | -0.79 |
| 2025-02-20 | -0.80 |
| 2025-02-19 | -0.82 |
| 2025-02-18 | -0.83 |
| 2025-02-14 | -0.86 |
| 2025-02-13 | -0.85 |
| 2025-02-12 | -0.85 |
| 2025-02-11 | -0.81 |
| 2025-02-10 | -0.88 |
| 2025-02-07 | -0.91 |
| 2025-02-06 | -0.94 |
| 2025-02-05 | -0.96 |
| 2025-02-04 | -0.86 |
| 2025-02-03 | -0.87 |
| 2025-01-31 | -0.91 |
| 2025-01-30 | -0.92 |
| 2025-01-29 | -0.89 |
| 2025-01-28 | -0.96 |
| 2025-01-27 | -0.86 |
| 2025-01-24 | -0.89 |
| 2025-01-23 | -0.83 |
| 2025-01-22 | -0.82 |
| 2025-01-21 | -0.85 |
| 2025-01-17 | -0.86 |
| 2025-01-16 | -0.86 |
| 2025-01-15 | -0.87 |
| 2025-01-14 | -0.95 |
| 2025-01-13 | -1.08 |
| 2025-01-10 | -1.26 |
| 2025-01-08 | -1.76 |
| 2025-01-07 | -1.78 |
| 2025-01-06 | -1.82 |
| 2025-01-03 | -1.93 |
| 2025-01-02 | -1.79 |
| 2024-12-31 | -1.74 |
| 2024-12-30 | -1.78 |
| 2024-12-27 | -1.84 |
| 2024-12-26 | -1.92 |
| 2024-12-24 | -1.84 |
| 2024-12-23 | -1.90 |
| 2024-12-20 | -1.88 |
| 2024-12-19 | -1.77 |
| 2024-12-18 | -1.74 |